Athersys Announces Expansion of Collaboration With Healios
Healios receives rights to develop and commercialize additional indications and Athersys receives $20 million in license fees, plus potential milestones payments and royalties
Discussions extended for China and other rights
CLEVELAND, Ohio, June 07, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that it has entered into an agreement with HEALIOS K.K. ("Healios") to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses for the development and commercialization in Japan of MultiStem® therapy for the treatment of acute respiratory distress syndrome ("ARDS") and of MultiStem cells used in combination with iPSC-derived cells for the treatment of certain organs. Healios also received an exclusive global license to develop and commercialize MultiStem cells, either as a standalone therapy or in combination with retinal pigmented epithelial ("RPE") cells for certain ophthalmological indications, and an expansion of its license to use Athersys technology to support its organ bud programs to include other transplantation areas. In exchange, Athersys receives $20 million in license fees, comprising $10 million paid from an escrow account established with the letter of intent signed in March 2018 and four installments of $2.5 million each to be paid in this and the next three quarters.
As part of the agreement, Athersys may also receive up to approximately $360 million in aggregate development and commercialization milestones for the licensed programs, as well as tiered double-digit royalties on MultiStem therapies developed for ARDS, and single-digit royalties for other licensed products. Under the terms of the agreement, Healios will also receive a credit of $10 million to be used against certain future development milestones and a right of first negotiation to broaden the field and territory related to MultiStem cells used in combination with iPSC-derived cells.
Also as part of the agreement, Healios has been granted a right of first negotiation regarding an exclusive option for a license to develop and commercialize MultiStem therapy for certain indications in China, and the potential inclusion of an additional indication to the Japan license.
"We are excited about completing this collaboration expansion with Healios," commented Dr. Gil Van Bokkelen, Chairman and CEO of Athersys. "It creates exciting opportunities in meaningful therapeutic areas where there is substantial unmet medical need and tangible value for both companies, building off of the work already conducted by Athersys in certain areas, including ARDS."
In association with Healios' recent equity investment and the expanded collaboration, Dr. Hardy Kagimoto, CEO of Healios, has been nominated for election to the Athersys Board of Directors at the next scheduled annual stockholders' meeting on June 18, 2018.
MultiStem® cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors produced in response to signals of inflammation and tissue damage. MultiStem therapy's potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent safety profile demonstrated in clinical studies, MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.
Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "suggest," "will," or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face that could cause actual results to differ materially from those implied by forward-looking statements are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as human therapeutics, such as the uncertainty regarding regulatory approval and market acceptance of our product candidates and our ability to generate revenues, including MultiStem for the treatment of ischemic stroke, acute myocardial infarction, spinal cord injury and acute respiratory distress syndrome and other disease indications, including graft-versus-host disease. These risks may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: our ability to work with Healios to reach an agreement on an option for China; the success of our collaboration with Healios and others, including our ability to reach milestones and receive milestone payments, and whether any products are successfully developed and sold so that we earn royalty payments; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our collaborators' ability to continue to fulfill their obligations under the terms of our collaboration agreements; the success of our efforts to enter into new strategic partnerships or collaborations and advance our programs; our ability to raise additional capital; results from our MultiStem clinical trials, including the MASTERS-2 Phase 3 clinical trial and the TREASURE trial in Japan; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials within the expected time frame or at all; changes in external market factors; changes in our industry's overall performance; changes in our business strategy; our ability to protect our intellectual property portfolio; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of our competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
William (B.J.) Lehmann
President and Chief Operating Officer
Tel: (216) 431-9900
Corporate Communications & Investor Relations
Tel: (216) 431-9900
Russo Partners, LLC
Tel: (212) 845-4271 or (858) 717-2310
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Athersys, Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00 | Pressmeddelande
Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00 | Pressmeddelande
Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H
Corline Biomedical AB: Läkemedelsverket ger tillstånd till klinisk prövning av Renaparin®6.8.2018 15:29 | Pressmeddelande
Corline Biomedical AB ("Corline") har i beslutsbrev från Läkemedelsverket erhållit tillstånd att genomföra klinisk prövning av läkemedelskandidaten Renaparin®. Läkemedelsverkets tillståndsmeddelande innebär att samtliga formella krav är uppfyllda för genomförande av studien RENAPAIR 01, som är en säkerhetsstudie i fas 1 omfattande totalt 18 patienter. Renaparin® är under utveckling för att förbättra njurtransplantation och administreras till njuren före transplantation i syfte att minska njurskador som annars kan uppstå då den mottagande patientens blodflöde kopplas ihop med donator-njuren. Corline meddelade i juni 2018 att man till Läkemedelsverket inlämnat ansökan om att få genomföra klinisk prövning av Renaparin® i en placebo-kontrollerad studie (RENAPAIR 01, Eudra-CT 2017-002075-25) där 9 patienter transplanteras med njurar som erhållit aktiv substans och 9 patienter får overksam placebo. Denna ansökan har nu godkänts av Läkemedelsverket. Studien inleds i Uppsala och genomförs däre
Cisco Schedules Conference Call for Q4 and Fiscal Year 2018 Financial Results1.8.2018 22:30 | Pressmeddelande
SAN JOSE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cisco has scheduled a conference call for Wednesday, August 15, 2018, at 1:30 PM (PT); 4:30 PM (ET) to announce its fourth quarter and fiscal year 2018 financial results for the period ending Saturday, July 28, 2018. Financial results will be released over GlobeNewswire via US National, European Technology Trade Media and Western Europe distribution circuits, after the close of the market on Wednesday, August 15, 2018. Cisco's quarterly earnings press release will be posted at www.cisco.com under the "Newsroom" section. Date: Wednesday, August 15, 2018 Time: 1:30 PM (PT); 4:30 PM (ET) To Listen via Telephone: 888-848-6507 212-519-0847 (for International Callers) RSVP: No RSVP is necessary To Listen via the Internet: We are pleased to offer a live and replay audio broadcast of the conference call with corresponding slides at https://investor.cisco.com. Replay: A telephone playback of the Q4 and FY2018 conference call is scheduled to be
Corline Biomedical AB: Corline erhåller andra utbetalningen från EU-kommissionen31.7.2018 08:45 | Pressmeddelande
Corline Biomedical AB ("Corline") meddelade i november 2016 att EU-kommissionen beslutat anslå ca 2,4 MEUR (ca 23,1 MSEK) till bolagets kliniska studie inom njurtransplantation med läkemedelskandidaten Renaparin ® . En första utbetalning från H2020-programmet till Corline om ca 1,2 MEUR genomfördes i mars 2017. Corline har nu sammanställt en rapport till EU-kommissionen i vilken framgår att samtliga delmål i projektets första fas är uppnådda. Därmed har kommissionen beslutat om fortsatt stöd och en andra delbetalning om ca 1 MEUR utbetalas inom kort. Corline erhåller anslaget för att genomföra den planerade kliniska fas 1-studien för Renaparin® som är under utveckling för att förbättra njurtransplantation. Den första projektfasen har bland annat innefattat GMP-produktion av läkemedelssubstansen och upprättande av ansökan om klinisk prövning samt inlämnande av densamma till Läkemedelsverket. Samtliga delmål i den första projektfasen har uppfyllts och rapporteringen om dessa har nu grans
RFA Accelerates Growth with Expansion in Luxembourg30.7.2018 15:00 | Pressmeddelande
RFA announces new private financial cloud in Luxembourg to accelerate growth and accommodate increased demand in technology regulation and cybersecurity LUXEMBOURG, July 30, 2018 (GLOBE NEWSWIRE) -- RFA, a next-gen managed IT service provider for the financial industry, announces a new private financial cloud in Luxembourg. This expansion allows RFA to accommodate accelerated growth in Europe and offer a portfolio of high quality private cloud services to both its existing and new financial services clients in Luxembourg, Madrid, Paris, and the wider region. Along with the London office, the new office doubles RFA's footprint in Europe and further bolsters the company's growth strategy. RFA has two highly secure, tier-one data centres in Luxembourg which meet the ISO27001 and SSAE16/Type II standards, which is key for firms regulated by the Commission de Surveillance du Sector Financier (CSSF). RFA is now ideally placed to provide a range of services to clients in this region, and offe
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum